Autolus Therapeutics (NASDAQ:AUTL) Shares Climb 6.2% – Should You Buy?

Posted by Brenda Bartman on Oct 2nd, 2026

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) rose 6.2% during trading on Wednesday. The company traded as high as $1.98 and last traded at $1.9750. Approximately 450,965 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 1,783,079 shares. The stock had previously closed at $1.86.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AUTL. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Get Our Latest Stock Report on AUTL

Autolus Therapeutics Stock Down 4.6%

The firm’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $1.71. The firm has a market capitalization of $492.40 million, a PE ratio of -1.75 and a beta of 2.15. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. As a group, research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.75 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently bought and sold shares of the business. Syncona Portfolio Ltd bought a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at about $26,625,152. Armistice Capital LLC boosted its stake in Autolus Therapeutics by 12.2% in the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,900,000 shares during the period. Alphabet Inc. bought a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $1,117,000. Arizona PSPRS Trust bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $298,000. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Autolus Therapeutics by 334.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 123,279 shares of the company’s stock worth $245,000 after purchasing an additional 94,873 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc (NASDAQ: AUTL) is a biopharmaceutical company developing and commercializing programmed T-cell therapies for cancer and other serious diseases. The company uses genetic engineering to create CAR T-cell products designed to recognize and eliminate cancer cells while improving control, persistence and safety compared with earlier-generation cell therapies.

Autolus’ lead product, obecabtagene autoleucel, also known as obe-cel and marketed in the United States as AUCATZYL, is a CD19-directed autologous CAR T-cell therapy.